SURMOUNT-1: The Primary Efficacy Trial
SURMOUNT-1 was a 72-week, randomised, double-blind, placebo-controlled Phase 3 trial evaluating Tirzepatide in 2,539 adults with obesity (BMI ≥30 or ≥27 with ≥1 weight-related comorbidity) without type 2 diabetes. Three doses were evaluated: 5mg, 10mg, and 15mg/week.
Primary endpoint results (mean body weight change):
- 5mg/week: −15.0%
- 10mg/week: −19.5%
- 15mg/week: −20.9%
- Placebo: −3.1%
At 15mg/week, 91% of participants achieved ≥5% weight loss, 57% achieved ≥20% weight loss. These were unprecedented outcomes for a pharmacological intervention in a clinical trial setting. The trial was published in the New England Journal of Medicine in 2022.
Secondary Endpoints and Metabolic Outcomes
Beyond weight reduction, SURMOUNT-1 documented significant improvements across multiple metabolic parameters at 72 weeks (15mg group vs placebo):
- Waist circumference: −14.4cm vs −3.3cm
- Systolic blood pressure: −6.2mmHg vs −0.4mmHg
- Triglycerides: −24.5% vs −3.5%
- Fasting glucose: −4.3mg/dL vs +2.0mg/dL
- Physical functioning (IWQOL-Lite-CT): significant improvement vs placebo
The breadth of cardiometabolic improvement across these endpoints was notable, supporting Tirzepatide as a compound with effects well beyond weight reduction alone.
SURMOUNT-2: Tirzepatide in Type 2 Diabetes
SURMOUNT-2 evaluated Tirzepatide in adults with both obesity and type 2 diabetes — a more metabolically complex population. Key findings at 72 weeks:
- 15mg/week: mean weight reduction of −15.7% (vs −3.3% placebo)
- HbA1c reduction: −2.4 percentage points at 15mg vs −0.6% for placebo
- 63% of participants in the 15mg group achieved HbA1c <5.7% (normal range)
The reduction in weight was approximately 5 percentage points lower than in SURMOUNT-1 (obesity without diabetes), which is consistent with findings for other GLP-1 class compounds — the presence of type 2 diabetes appears to attenuate peak weight loss response, potentially due to differences in insulin resistance, beta-cell function, or underlying metabolic state.
SURMOUNT-3 and SURMOUNT-4: Durability and Withdrawal
Two follow-on trials addressed critical questions about treatment durability:
SURMOUNT-3 evaluated Tirzepatide after a 12-week low-calorie diet lead-in phase (−7.5% weight loss pre-randomisation). Subsequent Tirzepatide treatment produced an additional −18.4% weight reduction at 72 weeks, for a total of −26.2% from original baseline — the highest mean weight reduction reported in any large-scale obesity pharmacotherapy trial to date.
SURMOUNT-4 addressed the durability question directly: participants who achieved weight loss on Tirzepatide were randomised to continue treatment or switch to placebo. Those who switched to placebo regained approximately 14% of their original body weight within 52 weeks, versus continued maintenance in the Tirzepatide group. This confirms the need for sustained treatment to maintain weight outcomes — a finding consistent across the GLP-1 class.
Implications for Dual Agonism Research
The SURMOUNT programme as a whole provides the most comprehensive clinical dataset for GLP-1/GIP dual agonism in obesity. Key research implications:
- GIP co-agonism meaningfully augments GLP-1 monotherapy outcomes — the 15% weight reduction seen in SURMOUNT-1 exceeds what Semaglutide achieves in comparable populations by approximately 6 percentage points
- The dose-response relationship is steep between 5mg and 10mg, then flattens between 10mg and 15mg — suggesting receptor saturation dynamics that may inform preclinical modelling
- Tirzepatide provides the most robust benchmark dataset for GLP-1/GIP dual agonism against which triple-agonist data (e.g. Retatrutide) can be compared